After Today’s Significant Increase, Is Cascadian Therapeutics Inc (USA) (CASC)’s Near-Term Analysis Positive?

September 17, 2017 - By Vivian Currie

The stock of Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) is a huge mover today! The stock increased 4.09% or $0.15 on September 15, reaching $3.82. About 847,604 shares traded or 164.62% up from the average. Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) has declined 30.85% since September 17, 2016 and is downtrending. It has underperformed by 47.55% the S&P500.
The move comes after 9 months positive chart setup for the $193.11 million company. It was reported on Sep, 17 by We have $4.13 PT which if reached, will make NASDAQ:CASC worth $15.45 million more.

Investors wait Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) to report on November, 6. its quarterly earnings Wall Street analysts expect $-0.28 earnings per share, up $0.26 or 48.15 % from last year’s $-0.54 same quarter earnings. Cascadian Therapeutics Inc (USA)’s Wall Street analysts see -6.67 % EPS growth, taking into account the $-0.30 EPS reproted in the previous quarter,

More notable recent Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) news were published by: which released: “Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in …” on July 11, 2017, also with their article: “Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress” published on January 05, 2017, published: “BRIEF-Mark Lampert says resigning from Cascadian Therapeutics’ board” on January 17, 2017. More interesting news about Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) were released by: and their article: “Cascadian Therapeutics’ (CASC) CEO Scott Myers on Q1 2017 Results – Earnings …” published on May 09, 2017 as well as‘s news article titled: “Cascadian Therapeutics: Worth Much More Than The Present Share Price” with publication date: March 23, 2017.

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The company has market cap of $193.11 million. The Firm focuses on the development of therapeutic products for the treatment of cancer. It currently has negative earnings. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor 2 inhibitor.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.